PDL BioPharma, Inc.

http://www.pdl.com

Protein Design Labs Incorporated, Freemont CA, United States of America.

PDL is a leader in the development of humanized monoclonal antibodies for the prevention and treatment of a variety of disease conditions. PDL currently has antibodies under development for autoimmune
Protein Design Labs Incorporated - Company Profile

Ticker -
PRW - Financial Information

PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009

Tuesday 27th of October 2009 17:15

INCLINE VILLAGE, Nev., Oct. 27 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Oppenheimer 20th Annual Healthcare Conference in New York City on Wednesday, November 4, 2009 at 9:40 a.m. Eastern Time

To access the live and subsequently archived webcast of the conference call, go to the company's website at http://www.pdl.com and click "Investors." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay will be available at www.pdl.com starting approximately three hours after completion of the webcast.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.

Source PR Newswire


www.prnewswire.co.uk

Browse news from 2009

Download PDF